Cortical and lesion remyelination in relapsing-remitting multiple sclerosis patients from the Opicinumab (Anti-LINGO-1) phase II clinical trial (Synergy). A validation study of the T1-weighted and T2-weighted ratio approach (RAPOR)
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
